Search Follow us
Refine By

Stock Exchange

Market Cap (m)

Analyst

Type of Publication

biolargo

1 - 2 of 2
Sort by: popularity | newest
Page  of 1
BioLargo

Moving on multiple fronts

QuickView | Pharmaceutical & healthcare | 20 Nov 2018

BioLargo made progress on multiple fronts during Q3 and subsequently toward becoming a fully fledged, diversified technology company. First, it announced that Clyra had received feedback from the FDA regarding the data necessary to complete the 510(k) application process, which should be finished in the next six months. Second, the company broke revenue records in October with BioLargo Engineering, Science & Technologies (BLEST) having its first break-even month. Finally, progress continues toward the 2019 launch of the AOS with the independent validation of the system’s capacity to eliminate micropollutants.

BioLargo

Incubating innovation in iodine

Initiation | Pharmaceutical & healthcare | 03 Oct 2018

BioLargo is a chemical innovation company developing and marketing novel products for a range of industries. Its core competency is the unique chemistry of iodine, which it has leveraged to develop an industrial odor control agent (currently marketed as CupriDyne Clean), an irrigation solution for chronic wounds and a wastewater treatment solution. The goal is to build independent companies around each of these products, which can then be spun out, with the BioLargo acting as a development engine. The company has expressed the intent to uplist to NASDAQ.